A5031408625- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Cell death mechanisms and regulation
- Immune cells in cancer
- Nanoplatforms for cancer theranostics
- Cancer-related Molecular Pathways
- Cell Adhesion Molecules Research
- Ubiquitin and proteasome pathways
- Phagocytosis and Immune Regulation
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Receptor Mechanisms and Signaling
- Cholesterol and Lipid Metabolism
- Extracellular vesicles in disease
- Neuroendocrine Tumor Research Advances
- Multiple Myeloma Research and Treatments
- Drug Transport and Resistance Mechanisms
- Chromatin Remodeling and Cancer
- Neuroblastoma Research and Treatments
- Inflammatory mediators and NSAID effects
- Advanced Proteomics Techniques and Applications
- Cancer, Lipids, and Metabolism
- Nanoparticle-Based Drug Delivery
- Photodynamic Therapy Research Studies
Kookmin University
2024-2025
Stanford University
2024-2025
Seoul National University
2018-2024
The tumor-specific efficacy of the most current anticancer therapeutic agents, including antibody-drug conjugates (ADCs), oligonucleotides, and photosensitizers, is constrained by limitations such as poor cell penetration low drug delivery. In this study, we addressed these challenges developing, a positively charged, amphiphilic Chlorin e6 (Ce6)-conjugated, cell-penetrating anti-PD-L1 peptide nanomedicine (CPPD1) with enhanced tissue permeability. CPPD1 molecule, bioconjugate hydrophobic...
Triple-negative breast cancer (TNBC) is characterized by its highly heterogeneous microenvironment and propensity for aggressive behavior, both of which represent, along with poor prognosis high incidence relapse, the main challenges curing disease. Although recent progress in targeted chemotherapy combinations has shown promising outcomes, conventional chemotherapeutic approaches have relied on exploiting expression certain molecules or proteins overexpressed cells as drug targets,...
Abstract Tumor heterogeneity is associated with the therapeutic failures of targeted therapies. To overcome such heterogeneity, a novel therapy proposed that could kill tumor populations diverse phenotypes by delivering nonselective cytotoxins to target‐positive cells as well surrounding via recurrent bystander killing effect. A representative prodrug prepared targets integrin αvβ3 and releases upon entering or caspase‐3. This allows αvβ3‐positive upregulate caspase‐3, which in turn,...
Despite recent breakthroughs in the development of direct KRAS inhibitors and modulators, no drugs targeting pan-KRAS mutant cancers are clinically available. Here, we report a novel strategy to treat using caspase-3 cleavable peptide–drug conjugate that exploits enhanced albumin metabolism altered deliver cytotoxic agent can induce widespread bystander killing effect tumor cells. Increased cancer cells induced apoptosis via intracellular uptake albumin-bound MPD1. This allowed upregulation...
Here we report a novel combination of caspase-cleavable peptide-doxorubicin conjugate (MPD-1) with CD47-antagonizing nanocage therapeutics for the treatment microsatellite-stable (MSS) colorectal cancer (CRC). MPD-1 (i) upregulated markers immunogenic cell death (ICD) in tumor, and increased co-stimulatory on dendritic cells (DCs), (ii) enhanced CD8+ T infiltration antigen presenting (APC) activation, (iii) showed negligible off-target immune-related toxicity compared to free dox. Then, CD47...
While conventional approaches for PTEN-loss cancers mainly focus on turning off growth promoting process through modulation of PI3K/AKT pathways, no effective therapeutic treatments that target cancer cells have yielded results. Moreover, targeted therapies, which are potent against only a subset with limited specificity, bring temporary response. Here, we report the development albumin-binding caspase-3 cleavable peptide-drug conjugate (PDC), utilizes enhanced albumin metabolism pathway in...
The selective cytotoxicity of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) to cancer cells but not normal makes it an attractive candidate for therapeutics. However, the disadvantages TRAIL such as physicochemical instability and short half-life limit its further clinical applications. In this study, was encapsulated into a novel anti-angiogenic nanocomplex both improved drug distribution at site enhanced anti-tumor efficacy. A prepared firstly by entrapping PEG-low...
Abstract Since the appearance of oxaliplatin, FOLFOX therapy is positioned as standard care for colorectal cancer (CRC). And after advent capecitabine, an oral prodrug 5-FU, both and CAPOX remain first-line treatment local advanced CRC. Even though 5-FU has approved more than two decades ago, orally available oxaliplatin not been developed yet. Oral chemotherapy garnered attention in era immunotherapy because form makes metronomic feasible. In this regard, we invented absorbable exploiting...
Abstract Although Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most well-known tumor driver gene with highest mutation rate in several types of cancer, there no effective mutant KRAS targeting drug yet. Recent studies have reported that macropinocytosis can be increased cancers mutation. Accordingly, attempts been made to deliver therapeutic agents using phenomena related albumin metabolism.To target cancer cells, we adopted a previously developed albumin-binding caspase-3...
Abstract Here we suggest a new effective strategy to overcome tumor heterogeneity for eradicating metastatic triple negative breast cancer (TNBC). As first strategy, applied combination therapy of caspase-3 mediated “targeting” (RGDEVD-DOX) and “maintaining” (EMC-DEVD-S-DOX) prodrugs, given in sequential manner. RGDEVD-DOX is designed target integrin αvβ3 induce apoptosis specifically cells. EMC-DEVD-S-DOX binds circulating albumin after administration show enhanced half-life accumulates at...
Here we suggest a new effective strategy to overcome tumor heterogeneity for eradicating metastatic triple negative breast cancer (TNBC). As first strategy, applied combination therapy of caspase-3 mediated "targeting" (RGDEVD-DOX) and "maintaining" (EMC-DEVD-S-DOX) prodrugs, given in sequential manner. RGDEVD-DOX is designed target integrin αvβ3 induce apoptosis specifically cells. EMC-DEVD-S-DOX binds circulating albumin after administration show enhanced half-life accumulates at site. In...